FJX1 and head and neck squamous cell carcinoma: Interestingly, it is feasible that a dual-antigenic peptide vaccine (PV1) comprises both MAGED4B and FJX1 peptides against head and neck squamous cell carcinoma, which is now under investigation in human safety (118).